Photo Therapeutics, Inc., leaders in light therapy, proudly receives its
6th FDA approval
CARLSBAD, Calif., March 12 /PRNewswire/ -- Photo Therapeutics, Inc. is pleased to announce it has received FDA approval on its new over-the-counter light therapy device, Omnilux New-U, for the treatment of periorbital wrinkles.
Omnilux New-U has been clinically proven to reduce periorbital wrinkles and to treat the visible signs of aging, using a combination of alternate treatments of infrared and red light twice a week for four weeks.
The clinical study conducted by Neil Sadick, Weill Medical College of Cornell University Department of Dermatology, New York, demonstrated a significant reduction in periorbital wrinkles and improvements in skin tone, clarity, smoothness and elasticity.
"This is a pivotal point in the history of the company and its development of light-based technologies. We are extremely proud of our medical heritage. We believe in producing light therapy devices that deliver optimized treatment parameters that have been rigorously tested and clinically proven, and our latest technological achievement is no different," said Sue D'Arcy, CEO of Photo Therapeutics, Inc. "We are excited that we can now offer Omnilux technology directly to the consumer marketplace without a prescription."
Photo Therapeutics, Inc. was established in 1998 with the right to the patented photodynamic therapy technology, the Paterson Lamp. Originating from the University of Manchester Institute of Science and Technology (UMIST) and years of cumulative research, the technology was launched commercially in 1998 as Omnilux.
The now widely recognized Omnilux Light Therapy system offers single
platform technology with the versatility of multiple treatment heads for
the treatment of acne, wrinkle reduction, skin rejuvenation, wound healing,
psoriasis and photodynamic therapy.
|SOURCE Photo Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved